Resupply of Paxil CR

GlaxoSmithKline PLC
27 June 2005


          GlaxoSmithKline Announces Resupply of Paxil CR to US Market

London and Philadelphia (27 June 2005) - GlaxoSmithKline (GSK) announced today
the availability of Paxil CR (paroxetine hydrochloride controlled release)
tablets in pharmacies across the United States.  Other markets will follow
shortly thereafter.

GSK committed to resupplying pharmacies and wholesalers by mid-year after
disruption of supply following the company's voluntary withdrawal of the product
in February due to manufacturing issues.  Both the company and the US Food and
Drug Administration (FDA) agreed at the time that the manufacturing issues posed
no significant safety issues for patients.  GSK has identified the source of the
manufacturing issues and has implemented revisions to those processes, as
certified by a third party.

Paxil CR is approved for the treatment of major depressive disorder, panic
disorder, social anxiety disorder and premenstrual dysphoric disorder.

With respect to Avandamet (rosiglitazone maleate/metformin hydrochloride)
tablets, the Company anticipates resupplying the distribution channels within
two weeks.

S M Bicknell
Company Secretary
27 June 2005

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
health care companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.


Enquiries:

UK Media enquiries:                   Philip Thomson          [phone]
                                      David Mawdsley          [phone]
                                      Chris Hunter-Ward       [phone]
                                      Alice Hunt              [phone]

US Media enquiries:                   Nancy Pekarek           [phone]
                                      Mary Anne Rhyne         [phone]
                                      Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:  Duncan Learmouth        [phone]
                                      Anita Kidgell           [phone]
                                      Jen Hill                [phone]

US Analyst/ Investor enquiries:       Frank Murdolo           [phone]
                                      Tom Curry               [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange